Completed PHASE2 INTERVENTIONAL NCT00020917

Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer

Pilot Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Combination With Irinotecan, Fluorouracil, and Leucovorin, and in Patients With Newly Diagnosed Stage IV Colorectal Carcinoma

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Colorectal Cancer

Interventions cetuximab fluorouracil irinotecan hydrochloride leucovorin calcium

Updated 5 times since 2017 Last updated: Jun 17, 2013 Started: Feb 28, 2001 Primary completion: Feb 29, 2004 Completion: Feb 29, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Colorectal Cancer, this trial is completed. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 5 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States